Sign up USA
Proactive Investors - Run By Investors For Investors
Why invest in WDC?
WideCells Group: THE INVESTMENT CASE

WideCells interims chart period of significant progress

The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases
man at a micrscope
INVESTMENT OVERVIEW: WDC The Big Picture
In July the company received a research licence, which will allow it carry out paid-for work to “drive developments” in stem cell therapies

Interims from WideCells Group PLC (LON:WDC) reveal the company has made tremendous progress - with two of its three divisions are now revenue generating.

The third, Wideacadamy, its education and training arm, will commence operations early next year.

WATCH: WideCells opens up its Manchester HQ and laboratory to Proactive Investors

The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases, including leukaemia and lymphoma. The storage and research operation is the core WideCells business.

Insurance product

It has also developed an insurance plan that will allow people to pay for treatments using the umbilical material. This is called CellPlan, which already now making money for the firm.

In the six months to June 30 WideCells has passed a series of landmarks. These include securing a deal with Biovault, which has 25,000 cord samples; an agreement with Brazilian storage group Hemcord; and the creation of an e-commerce platform.

READ: WideCells Group to develop stem cells education platform

WideCells says it has a “strong growth pipeline” and is “actively assessing a number of agreements with additional cord blood storage facilities”.

It is also building a portfolio of global stem cell storage units around its current operations in Brazil and Manchester.

Research licence

Meanwhile, in July it received a research licence, which will allow it carry out paid-for work to “drive developments” in stem cell therapies.

On top of that the company was ranked 21 in the Global DISRUPT 100 list of the 100 most disruptive start-ups and received a nomination as Life Science IPO of the year at the Biotech&Money awards.

Changing the landscape

"I firmly believe WideCells Group is set to change our future medical landscape,” said chief executive chief executive Joao Andrade.

WATCH: WideCells combining education and tech with new software platform

“By creating the world's first end-to-end service solution, we are committed to making cord blood stem cell treatment accessible and affordable globally and I believe the repercussions of this are set to be huge.”

As is common for a company at this formative stage of its commercial development, WideCells was lossmaking – to the tune of £880,397 for the six months to June 30. Revenues for the period were £25,000. More importantly, it had cash at the period-end of £868,829, which bolstered by a further £750,000 injection following a share placing in August.

View full WDC profile View Profile

WideCells Group Timeline

Video
October 12 2017
Newswire
October 12 2017

Related Articles

couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use